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Abstract
Background: Antimicrobial stewardship activities are essential to improve prudent antimicrobial use. The aim of
the present study was to evaluate changes in antimicrobial prescriptions in cats after the introduction of prudent
use guidelines promoted by an online antimicrobial stewardship tool (AntibioticScout.ch) in Switzerland. Data from
792 cats presented to two university hospitals and 14 private practices in 2018 were included and compared to 776
cases from 2016. Cats were diagnosed with acute upper respiratory tract disease (aURTD), feline lower urinary tract
disease (FLUTD) and abscesses. Clinical history, diagnostic work-up and antimicrobial prescriptions (class, dosage,
duration) were assessed. Type and proportions [95% confidence intervals] of antimicrobial prescriptions were
compared between the two evaluation periods and a mixed effects logistic regression model was applied to
evaluate compliance with Swiss prudent use guidelines.
Results: From 2016 to 2018, the proportion of antimicrobial prescription in all included cases decreased from 75.0%
[71.8–78.0] to 66.7% [63.3–69.9]; this decrease was most pronounced for treatments at university hospitals (67.1%
[59.5–74.0] to 49.3% [40.9–57.8]) and for cats with FLUTD (60.1% [54.6–65.4] to 48.8% [43.2–54.4]). Use of 3rd
generation cephalosporins in private practices declined from 30.7% [26.5–35.1] to 22.1% [18.4–26.2], while overall
use of non-potentiated aminopenicillins increased from 19.6% [16.4–23.0] to 27.8% [24.1–31.9]. In cases where
antimicrobial therapy was indicated, compliance with guidelines did not increase (33.3% [26.6–40.6] to 33.5% [27.2–
40.2]), neither at universities nor in private practices. On the other hand, antimicrobial treatment was more often
withheld in cases with no indication for antimicrobial therapy (35.6% [30.1–41.4] to 54.0% [47.6–60.4]); this was
found for private practices (26.7% [20.8–33.4] to 46.0% [38.4–53.7]) and for aURTD cases (35.0% [26.5–44.2] to 55.4%
[44.7–65.8]).
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Conclusions: Overall proportions of antimicrobial prescription, unjustified antimicrobial therapy and, in private
practices, use of 3rd generation cephalosporins decreased from 2016 to 2018 for the investigated feline diseases.
However, overall compliance with Swiss prudent use guidelines was still low, implying that further efforts are
required to foster prudent antimicrobial use in cats.
Keywords: Antimicrobial stewardship program, Prescription guidelines, Antibiotics, Prescription patterns,
Companion animals, HPCIA, Highest priority critically important antimicrobial, One Health
Background
A One Health approach is required to combat the devel-
opment and spread of antimicrobial-resistant bacteria [1,
2]. Antimicrobial use is thought to be a major driving
force towards antimicrobial resistance [3, 4] and over-
prescription of antimicrobials seems to be common in
human and veterinary medicine [5–9]. The largest pro-
portion of antimicrobials sold in Europe are used to
treat food producing animals and the role of companion
animals in this context has been neglected for a long
time [10]. However, highest priority critically important
antimicrobials (HPCIAs) are commonly administered to
companion animals [11–13]. In cats, the extensive use of
3rd generation cephalosporins, particularly the long-
lasting cefovecin, is problematic [12–18]. This can foster
the development and spread of antimicrobial resistant
microorganisms in veterinary patients, e.g. extended-
spectrum beta-lactamase producing Enterobacteriaceae
[19, 20]. Numerous reports support a transmission of re-
sistant bacteria from companion animals to humans,
underlining the need to also promote prudent anti-
microbial use in small animal medicine [21–27].
Antimicrobial stewardship programs aim to preserve
the effectiveness of available antimicrobial agents and
include different approaches, such as staff education,
infection prevention and control, surveillance of anti-
microbial resistance and health-care associated infec-
tions, propagation of prudent antimicrobial use and
restrictions for HPCIAs [28, 29]. A common tool to en-
hance prudent antimicrobial use are prescription guide-
lines. In veterinary medicine, various countries and
organizations have developed guidelines that are adapted
to national requirements or local needs [30–35]. To
date, only very few studies have investigated the impact
of those guidelines on antimicrobial prescription in com-
panion animals. A decrease of antimicrobial prescrip-
tions after the introduction of prudent use guidelines
has been reported in Flemish small animal practices and
in a veterinary teaching hospital in Canada [9, 36]. In a
Europe-wide survey, veterinarians in countries with na-
tional policies for antimicrobial use, as for example
Sweden, seemed to prescribe critically important antibi-
otics less frequently than in countries without such
policies [11]. In Denmark, 65% of companion animal
practitioners reported in a questionnaire-based survey
that the Danish national antibiotic use guidelines had in-
fluenced their prescription habits [37].
In Switzerland, the ban of antimicrobial growth pro-
moters in 1999 together with other regulations and
activities (e.g. drug recording requirements in food-
producing animals, herd management by specialized
veterinarians, disease eradication and vaccination pro-
grams) were associated with a reduction in antimicrobial
use [38]. Since November 2015, a national Strategy on
Antimicrobial Resistance (StAR) reinforces these
measures [39]. Antimicrobial sale numbers in
Switzerland showed a decrease of 41.1% between 2012
and 2018, while sales of antimicrobials exclusively regis-
tered for companion animals dropped by 13.4% [40].
However, population-adjusted antimicrobial sales for
food-producing animals are still high compared to coun-
tries such as Sweden, Norway, Finland and Iceland,
which emphasizes the need for further actions [10].
In December 2016, an online antimicrobial steward-
ship tool (AntibioticScout.ch) was introduced to pro-
mote Swiss guidelines on prudent antimicrobial use.
This tool contains specific recommendations on anti-
microbial prescription for various disease complexes
[41–43]. AntibioticScout.ch has been published and dis-
seminated through different channels, including the offi-
cial journal of the Swiss Veterinary Society [42, 43], in
newsletters of the Swiss Veterinary Society, on the web-
site of the Federal Food Safety and Veterinary Office
[44], on the website of the Institute of Veterinary
Pharmacology and Toxicology of the University of
Zurich [41], and in numerous continued education
events for practitioners. The tool is accessed between
300 and 600 times a day (status March 2020) and intro-
duced to each veterinary student in Switzerland. A previ-
ous study evaluated the a priori compliance with the
guidelines for cats with acute upper respiratory tract dis-
ease (aURTD), feline lower urinary tract disease
(FLUTD) and abscesses in Switzerland in 2016, before
implementation of AntibioticScout.ch. The study re-
ported an overall poor compliance of 17–24%, and 3rd
generation cephalosporins were the second most
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commonly prescribed antibiotic class in these patients
[45]. The present study is a follow-up investigation to
examine changes of antimicrobial prescriptions in cats
in Switzerland after launching the online antimicro-
bial stewardship tool AntibioticScout.ch. For this
purpose, data for 2016 and 2018 from 14 private vet-
erinary practices and two university hospitals on cats
with aURTD, FLUTD and abscesses were compared
and prescription patterns and compliance with guide-
lines evaluated.
Results
Case characteristics
A total of 792 cases (aURTD, n = 244; FLUTD, n =
324; abscesses, n = 224) was included in 2018 and
compared to 776 cases from 2016 [45]. Case charac-
teristics are given in Table 1. There was no difference
in the proportion of cases presented to university
hospitals compared to private practices between 2016
and 2018. Moreover, sex and breed distribution for
the three disease complexes was not different between
the two evaluation periods (Table 1), as well as age
distribution in cases with FLUTD and abscesses.
However, cats suffering from aURTD in 2018 were
significantly older compared to cats in 2016
(Additional file 1).
The proportion of cases that had been pretreated with
antibiotics or those hospitalized was not different be-
tween 2016 and 2018 for the three disease complexes
(aURTD, FLUTD and abscesses, Table 1). As in 2016
[45], the proportion of cases pretreated with antibiotics
or hospitalized was higher at the university hospitals
compared to private practice cases in 2018 (university
hospitals vs. private practices, proportion [95% confi-
dence interval (CI)]: pretreatment: 20.1% [13.9–27.6] vs.
3.9% [2.5–5.6]; hospitalization: 67.4% [59.1–74.9] vs.
10.8% [8.5–13.5]). In the pretreated cases, the antimicro-
bial class was either continued (2016: 25.5% [14.7–39.0];
2018: 42.6% [29.2–56.8]) or switched (2016: 30.9%
[19.1–44.8]; 2018: 31.5% [19.5–45.6]) or antibiotic treat-
ment was stopped (2016: 23.6% [13.2–37.0]; 2018: 22.2%
[12.0–35.6]). In some cases the antimicrobial class used
for pretreatment was unknown (2016: 20.0% [10.4–33.0];
2018: 3.7% [0.5–12.7]).
Table 1 Characteristics of cases in 2016 and 2018 for cats with aURTDa, FLUTDb and abscesses
Parameter aURTDa FLUTDb Abscesses
2016 2018 2016 2018 2016 2018
Total number of cases n = 227 n = 244 n = 333 n = 324 n = 216 n = 224
% [CI]c % [CI]c % [CI]c % [CI]c % [CI]c % [CI]c
Treatment location University hospital 18.9 [14.1–24.7] 11.5 [7.8–16.2] 39.0 [33.8–44.5] 35.8 [30.6–41.3] 0.0d 0.0d
Private practice 81.1 [75.3–85.9] 88.5 [83.8–92.2] 61.0 [55.5–66.2] 64.2 [58.7–69.4] 100.0d 100.0d
Sex Female 43.6 [37.1–50.3] 39.8 [33.6–46.2] 42.0 [36.7–47.5] 40.7 [35.3–46.3] 29.6 [23.6–36.2] 31.3 [25.2–37.8]
Male 53.3 [46.6–59.9] 55.3 [48.9–61.7] 57.4 [51.8–62.7] 57.1 [51.5–62.6] 68.5 [61.9–74.7] 65.6 [59.0–71.8]
Unknown 3.1 [1.2–6.3] 4.9 [2.6–8.4] 0.6 [0.1–2.2] 2.2 [0.9–4.4] 1.9 [0.5–4.7] 3.1 [1.3–6.3]
Breed Purebred 19.4 [14.5–25.1] 20.9 [16.0–26.5] 20.7 [16.5–25.5] 21.6 [17.2–26.5] 6.5 [3.6–10.6] 7.6 [4.5–11.9]
Mixed breed 75.8 [69.7–81.2] 75.0 [69.1–80.3] 74.2 [69.1–78.8] 73.5 [68.3–78.2] 88.0 [82.9–92.0] 87.5 [82.4–91.5]
Unknown 4.8 [2.4–8.5] 4.1 [2.0–7.4] 5.1 [3.0–8.0] 4.9 [2.8–7.9] 5.6 [2.9–9.5] 4.9 [2.5–8.6]
Pretreatment Yese 9.3 [5.8–13.8] 8.2 [5.1–12.4] 8.1 [5.4–11.6] 8.6 [5.8–12.2] 3.2 [1.3–6.6] 2.7 [1.0–5.7]
Unknown 2.6 [1.0–5.7] 2.0 [0.7–4.7] 2.4 [1.0–4.7] 1.2 [0.3–3.1] 0.9 [0.1–3.3] 0.4 [0.0–2.5]
Hospitalization Yese 15.9 [11.4–21.3] 10.7 [7.1–15.2] 36.0 [30.9–41.4] 36.7 [31.5–42.2] 6.0 [3.2–10.1] 9.8 [6.3–14.5]
Indication for AMUf Yes 28.2 [22.4–34.5] 32.0 [26.2–38.2] 17.1 [13.2–21.6] 17.0 [13.1–21.5] 30.1 [24.1–36.7] 36.6 [30.3–43.3]
No 52.9 [46.1–59.5] 37.7 [31.6–44.1] 31.8 [26.9–37.1] 33.6 [28.5–39.1] 30.6 [24.5–37.2] 21.0 [15.8–26.9]
Unknown 18.9 [14.1–24.7] 30.3 [24.6–36.5] 51.1 [45.5–56.5] 49.4 [43.8–55.0] 39.4 [32.8–46.2] 42.4 [35.9–49.2]
Diagnostic work-upg Yese 11.9 [8.0–16.8] 8.2 [5.1–12.4] 52.3 [46.7–57.7] 56.8 [51.2–62.3] NAh NAh
Local wound treatment Yese NAh NAh NAh NAh 72.2 [65.7–78.1] 81.3 [75.5–86.1]
Unknown NAh NAh NAh NAh 5.6 [2.9–9.5] 5.8 [3.1–9.7]
Drainage Yese NAh NAh NAh NAh 15.3 [10.8–20.8] 21.4 [16.2–27.4]
Non-overlapping 95% confidence intervals are shown in bold; Data from cases from 2016 has been published previously [45]; aaURTD, acute upper respiratory
tract disease; bFLUTD, feline lower urinary tract disease; cCI, 95% confidence interval; dCases with abscesses were only recruited in private practices (see methods);
eValues for the category “no” (reference group) are not shown; fAMU, antimicrobial use; gPCR for feline herpesvirus-1 and feline calicivirus in cases with aURTD;
sediment analysis or culture of aseptically collected urine in cases with FLUTD; hNA, not applicable
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Diagnostic work-up
The proportion of cases with aURTD tested for feline
herpesvirus-1 and feline calicivirus by PCR did not differ
between 2016 and 2018 (Table 1). As in 2016 [45], this
diagnostic work-up was more commonly performed at
the university hospitals compared to private practices in
2018 (university hospitals: 57.1% [37.2–75.5]; private
practices: 1.9% [0.5–4.7]).
Urine sediment analysis or bacterial culture from an
aseptically collected urine were performed in similar
proportions of cases with FLUTD in 2016 and 2018
(Table 1). The proportion of cases receiving this
diagnostic work-up increased in private practices from
2016 to 2018 (27.1% [21.1–33.8] to 43.8% [36.9–50.8]).
Despite this increase, diagnostic work-up in cats with
FLUTD was still more common at university hospitals
(80.2% [71.7–87.0]) compared to private practices in
2018. Among cases with diagnostic work-up, a total of
36.9% [29.4–45.0] were diagnosed with bacteriuria in
2018 and similar numbers were obtained in 2016 (37.0%
[29.6–44.8]).
Antimicrobial prescriptions in 2016 and 2018 overall
Proportions of prescribed antimicrobial classes in 2016
and 2018 are shown in Fig. 1. Details on antimicrobial
prescriptions for all cases in 2016 and 2018, and data
separated for university hospitals and private practices,
are shown in Additional file 2.
Considering all cases of cats with aURTD, FLUTD or
abscesses, the proportion of cases receiving antimicrobial
treatment decreased from 2016 to 2018 (2016: 75.0%
[71.8–78.0]; 2018: 66.7% [63.3–69.9]); this decline was
distinct at the university hospitals (2016: 67.1% [59.5–
74.0] of all cases; 2018: 49.3% [40.9–57.8] of all cases),
but some reduction was also evident in private practice
(2016: 77.3% [73.7–80.6] of all cases; 2018: 70.5% [66.8–
74.0] of all cases). In 2018, the proportion of cases re-
ceiving antimicrobial treatment was higher in private
practices compared to university hospitals.
When considering all cases receiving antimicrobials,
the proportion of cases treated with HPCIAs did not
change from 2016 to 2018 (2016: 33.0% [29.2–37.0];
2018: 28.8% [25.0–32.9]), neither at the university hospi-
tals (2016: 12.9% [7.4–20.4]; 2018: 12.7% [6.0–22.7]) nor
in private practices (2016: 38.0% [33.6–42.6]; 2018:
31.3% [27.1–35.8]). On the other hand, the proportion
of cases treated with 3rd generation cephalosporins de-
creased in private practices (2016: 30.7% [26.5–35.1] of
treated cases; 2018: 22.1% [18.4–26.2] of treated cases),
and overall, the proportion of cases treated with non-
potentiated aminopenicillins increased (Fig. 1). Pre-
scribed HPCIAs included 3rd generation cephalosporins,
macrolides and quinolones; fourth or higher generation
cephalosporins, ketolides, glycopeptides and polymyxins
have not been prescribed to patients in this study. Com-
bination or serial therapy was more common in 2018 than
in 2016 (2016: 17.0% [14.0–20.3] of treated cases; 2018:
Fig. 1 Comparison of antimicrobial classes prescribed in 2016 and 2018. Percentages of prescribed antimicrobial classes (dots) per total number
of cases with antimicrobial treatment in 2016 (n = 582, filled dots) and 2018 (n = 528, empty dots) and corresponding 95% confidence intervals
(lines). *Others (antimicrobial classes used in ≤ 2% of prescriptions) included amphenicoles, lincosamides, macrolides, penicillins, nitroimidazoles.
Gen., generation; pot., potentiated
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27.7% [23.9–31.7] of treated cases). Details on prescribed
combination therapies are shown in Additional file 3.
Antimicrobial prescriptions in 2016 and 2018 for cats
with aURTD, FLUTD and abscesses
Details of antimicrobial prescriptions in cats with
aURTD, FLUTD and abscesses are given in Table 2.
From 2016 to 2018, the proportion of antimicrobial
treatments in cats with aURTD did not change, but ser-
ial/combination therapy was more frequently used in
2018. Treatment duration in cats with aURTD was simi-
lar in 2016 compared to 2018 (Table 2).
In 2018, less cases with FLUTD were treated with anti-
microbials compared to 2016 and treatment duration de-
creased. Proportions of antimicrobial classes used in cats
with FLUTD did not change (Table 2).
In cats with abscesses, the proportion of antimicrobial
prescriptions was very high in 2018 (91.5%) and did not
change compared to 2016. The antimicrobial classes pre-
scribed were similar in both evaluation periods and
treatment duration did not change between 2016 and
2018 (Table 2).
Compliance with Swiss prudent use guidelines
To evaluate compliance with guidelines, cases were sepa-
rated into those with and without indication for
antimicrobial treatment. Cases with insufficient data for
classification were excluded from analysis (private prac-
tices, 2016: n = 286, 2018: n = 304; universities, 2016: n =
12, 2018: n = 25). Exclusion of cats with FLUTD (2016:
n = 170, 2018: n = 160) was mainly due to lack of diag-
nostic work-up, and in cats with aURTD (2016: n = 43,
2018: n = 74) and abscesses (2016: n = 85, 2018: n = 95)
due to lack of documentation of clinical signs. Details on
compliance with Swiss prudent use guidelines promoted
by AntibioticScout.ch for the three disease complexes
are shown in Table 3. Details for all cases and separated
for the university hospitals and private practices are
given in Additional file 4.
Overall, the proportion of correct treatment decisions
in cases in which antimicrobials were indicated did not
increase from 2016 to 2018 (2016: 33.3% [26.6–40.6];
2018: 33.5% [27.2–40.2]), neither at the university hospi-
tals (2016: 26.8% [16.9–38.6]; 2018: 42.2% [27.7–57.8])
nor in private practices (2016: 37.4% [28.5–46.9]; 2018:
31.2% [24.3–38.7]). When cases without indication for
antimicrobial treatment were analyzed, more cases were
treated following Swiss guidelines in 2018 compared to
2016 (2016: 35.6% [30.1–41.4]; 2018: 54.0% [47.6–60.4]),
i.e. the proportion of cases with unjustified antimicrobial
therapies has declined. This increase in adherence to the
guidelines in cases without indication for antimicrobial
Table 2 Antimicrobial prescriptions in 2016 and 2018 for cases with aURTDa, FLUTDb and abscesses
Parameter aURTDa FLUTDb Abscesses
2016 2018 2016 2018 2016 2018
Total number of cases n = 227 n = 244 n = 333 n = 324 n = 216 n = 224
% [CI]c % [CI]c % [CI]c % [CI]c % [CI]c % [CI]c
Antimicrobial treatment Yesd 77.1 [71.1–82.4] 67.6 [61.4–73.5] 60.1 [54.6–65.4] 48.8 [43.2–54.4] 95.8 [92.2–98.1] 91.5 [87.1–94.8]
Details of antimicrobial treatment n = 175 n = 165 n = 200 n = 158 n = 207 n = 205
% [CI]c % [CI]c % [CI]c % [CI]c % [CI]c % [CI]c
Potentiated aminopenicillin 40.0 [32.7–47.7] 49.1 [41.2–57.0] 60.5 [53.4–67.3] 69.6 [61.8–76.7] 63.8 [56.8–70.3] 63.4 [56.4–70.0]
3rd generation cephalosporin 28.0 [21.5–35.3] 23.6 [17.4–30.9] 25.5 [19.6–32.1] 13.9 [8.9–20.3] 25.1 [19.4–31.6] 20.5 [15.2–26.7]
Aminopenicillin 23.4 [17.4–30.4] 29.1 [22.3–36.7] 11.5 [7.4–16.8] 20.9 [14.8–28.1] 24.2 [18.5–30.6] 32.2 [25.9–39.1]
Fluoroquinolone 4.0 [1.6–8.1] 8.5 [4.7–13.8] 12.5 [8.3–17.9] 15.8 [10.5–22.5] 2.4 [0.8–5.5] 3.4 [1.4–6.9]
Tetracycline 16.0 [10.9–22.3] 20.6 [14.7–27.6] 0.5 [0.0–2.8] 0.0 [0.0–2.3] 0.0 [0.0–1.8] 0.5 [0.0–2.7]
1st generation cephalosporin 0.6 [0.0–3.1] 0.0 [0.0–2.2] 3.0 [1.1–6.4] 1.3 [0.2–4.5] 5.8 [3.0–9.9] 9.3 [5.7–14.1]
Otherse 4.0 [1.6–8.1] 3.6 [1.3–7.7] 0.5 [0.0–2.8] 0.0 [0.0–2.3] 2.4 [0.8–5.5] 3.9 [1.7–7.5]
HPCIAsf Yesd 33.7 [26.8–41.2] 33.9 [26.8–41.7] 38.0 [31.2–45.1] 29.7 [22.7–37.5] 27.5 [21.6–34.2] 23.9 [18.2–30.3]
Serial/combination therapy Yesd 14.3 [9.5–20.4] 30.3 [23.4–37.9] 13.0 [8.7–18.5] 19.6 [13.7–26.7] 23.2 [17.6–29.5] 31.7 [25.4–38.6]
Treatment duration (days)g n = 140 n = 127 n = 178 n = 134 n = 153 n = 164
Median (range) Median (range) Median (range) Median (range) Median (range) Median (range)
12 (4–37) 10 (1–21) 13 (1–56)h 9.5 (1–42)h 9 (1–28) 9 (2–28)
Non-overlapping 95% confidence intervals or comparisons with p-values < 0.05 (for treatment duration) are shown in bold; Data from cases from 2016 has been
published previously [45]; aaURTD, acute upper respiratory tract disease; bFLUTD, feline lower urinary tract disease; cCI, 95% confidence interval; dValues for the
category “no” (reference group) are not shown; eOthers (antimicrobial classes used in ≤ 2% of prescriptions) included amphenicoles, lincosamides, macrolides,
penicillins, nitroimidazoles; fHPCIAs, highest priority critically important antimicrobials; gTreatment duration was unknown for numbers not listed (2016: n = 111;
2018: n = 103); hp-value = 0.006
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treatment was found in private practices (2016: 26.7%
[20.8–33.4]; 2018: 46.0% [38.4–53.7]) and to some ex-
tend also at the university hospitals (2016: 55.6% [44.7–
66.0]; 2018: 73.0% [61.4–82.6]).
When compliance with consensus guidelines was ana-
lyzed for cats with aURTD, a similar trend was seen.
The proportion of correct treatment decisions in cases
in which antimicrobials were indicated did not increase,
but compliance increased in cases without an indication
for antimicrobial treatment (Table 3). Compliance with
treatment recommendations was generally low, mostly
due to use of potentiated aminopenicillins instead of rec-
ommended non-potentiated aminopenicillins or doxy-
cycline (Table 3). In cases with FLUTD or abscesses, the
proportion of correct treatment decisions did not change
between 2016 and 2018, neither in cases with or without
indication for antimicrobial treatment (Table 3). Treat-
ment duration and prescription of an antibiotic class not
recommended by the guidelines, especially use of poten-
tiated instead of non-potentiated aminopenicillins, was
common in cats with FLUTD. In cats with abscesses,
unnecessary treatments and treatments exceeding the
recommended duration were frequent (Table 3).
Mixed effects logistic regression model
A mixed effects logistic regression model was calculated
for cases with and without an indication for antibiotic
treatment (Table 3) to assess compliance of prescrip-
tions with AntibioticScout.ch guidelines. In cases with
an indication for antimicrobial treatment, the proportion
of cases in which the guidelines were followed did not
change from 2016 to 2018 (OR 1.0 [0.6–1.6]). In these
cases, cats with FLUTD or abscesses were more often
treated according to the guidelines than cats with
aURTD, independently of the evaluation period
(FLUTD: OR 5.1 [2.6–10.0]; abscess: OR 5.4 [2.9–10.0]).
In cases without indication for antimicrobial treatment,
guidelines were followed more frequently in the respect-
ive cases in 2018 than in 2016 (OR 2.4 [1.6–3.5]). In
cases without indication for antimicrobial treatment,
guidelines were followed less often in cats with abscesses
compared to cats with aURTD (OR 0.1 [0.0–0.2]). On
the other hand, in cats with FLUTD, a tendency towards
more treatments in agreement with the guidelines was
observed in comparison to cats with aURTD (OR 1.6
[1.0–2.7]). No significant interaction was found between
year and disease complex.
Discussion
The results of this study indicate an overall trend to-
wards a more prudent antimicrobial prescribing practice
in cats in Switzerland after the introduction of an online
antimicrobial stewardship tool (AntibioticScout.ch) in
December 2016. Between 2016 and 2018, overall propor-
tions of antimicrobial use in cats with aURTD, FLUTD
and abscesses declined, as well as prescriptions of 3rd
generation cephalosporins in private practices. Further-
more, antimicrobials were more commonly withheld in
Table 3 Compliance with the guidelines in 2016 and 2018 for cases with aURTDa, FLUTDb and abscesses
Category aURTDa FLUTDb Abscesses
2016 2018 2016 2018 2016 2018
AMUc indicated n = 64 n = 78 n = 57 n = 55 n = 65 n = 82
% [CI]d % [CI]d % [CI]d % [CI]d % [CI]d % [CI]d
Guidelines followed 10.9 [4.5–21.2] 16.7 [9.2–26.8] 38.6 [26.0–52.4] 45.5 [32.0–59.4] 50.8 [38.1–63.4] 41.5 [30.7–52.9]
Guidelines not followed
a. Different dose/duration 6.3 [1.7–15.2] 2.6 [0.3–9.0] 1.8 [0.0–9.4] 5.5 [1.1–15.1] 24.6 [14.8–36.9] 34.1 [24.0–45.4]
b. Different antimicrobial class 75.0 [62.6–85.0] 67.9 [56.4–78.1] 54.4 [40.7–67.6] 38.2 [25.4–52.3] 21.5 [12.3–33.5] 22.0 [13.6–32.5]
c. Unjustified non-use 7.8 [2.6–17.3] 12.8 [6.3–22.3] 5.3 [1.1–14.6] 10.9 [4.1–22.2] 3.1 [0.4–10.7] 2.4 [0.3–8.5]
AMUc not indicated n = 120 n = 92 n = 106 n = 109 n = 66 n = 47
% [CI]d % [CI]d % [CI]d % [CI]d % [CI]d % [CI]d
Guidelines followed 35.0 [26.5–44.2] 55.4 [44.7–65.8] 55.7 [45.7–65.3] 67.9 [58.3–76.5] 4.5 [0.9–12.7] 19.1 [9.1–33.3]
Treatment duratione n = 140 n = 127 n = 178 n = 134 n = 153 n = 164
% [CI]d % [CI]d % [CI]d % [CI]d % [CI]d % [CI]d
Guidelines followed 89.3 [82.9–93.9] 88.2 [81.3–93.2] 44.4 [37.0–52.0] 54.5 [45.7–63.1] 39.2 [31.4–47.4] 39.6 [32.1–47.6]
Guidelines not followed
a. Too long 10.7 [6.1–17.1] 10.2 [5.6–16.9] 50.6 [43.0–58.1] 38.8 [30.5–47.6] 57.5 [49.3–65.5] 56.1 [48.1–63.8]
b. Too short 0.0 [0.0–2.6] 1.6 [0.2–5.6] 5.1 [2.3–9.4] 6.7 [3.1–12.4] 3.3 [1.1–7.5] 4.3 [1.7–8.6]
Non-overlapping 95% confidence intervals are shown in bold; Data from cases from 2016 has been published previously [45]; aaURTD, acute upper respiratory
tract disease; bFLUTD, feline lower urinary tract disease; cAMU, antimicrobial use; dCI, 95% confidence interval; eTreatment duration is unknown for numbers not
listed (2016: n = 111; 2018: n = 103)
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cases where antimicrobial treatment was not recom-
mended by the guidelines. This decrease of antimicrobial
use is also supported by total sale statistics of antimicro-
bials registered for companion animals in Switzerland,
which showed a decline of 4.9% during the same
period [40]. Other studies also reported a reduction
of antimicrobial prescriptions in both human and
small animal medicine after the implementation of
antimicrobial stewardship programs, underlining that
these activities could have an impact on treatment
strategies [9, 36, 46–49].
The reduction in use of 3rd generation cephalosporins
from 30.7 to 22.1% in the private practices in 2018 is en-
couraging. The overall proportion of treatments with
HPCIAs, however, did not decrease, which is possibly
due to a slight increase in use of fluoroquinolones in
2018. Furthermore, the proportion of cases receiving
HPCIAs was still very high, especially in private practices
(31.3%). HPCIAs are not recommended for any of the
investigated diseases and should only be used based on
antimicrobial susceptibility testing. A significant de-
crease in use of 3rd generation cephalosporins in the
university hospitals was not found (7.8 to 2.8%). How-
ever, this antibiotic class was already infrequently used
in 2016.
Despite an overall decline in antimicrobial prescrip-
tions, over-prescription was still common in 2018, espe-
cially in cats with abscesses. A total of 91.5% of the cats
with abscesses in 2018 received antimicrobial therapy,
compared to 67.6% of cases with aURTD and 48.8% of
cats with FLUTD. This is striking because various stud-
ies from human medicine indicate that cure rates in un-
complicated skin abscesses are not influenced by
antibiotic use as long as appropriate local wound therapy
is applied [50–52]. Interestingly, 81.3% of the cats with
abscesses in 2018 received a local wound treatment and
21.4% a drainage. This highlights that antimicrobials, al-
though not indicated, are often prescribed in addition to
local wound therapy in cats with abscesses. Fear of com-
plications or owner dissatisfaction were listed as reasons
for prescribing antimicrobials when not indicated in a
recent interview-based study [16]. Veterinarians reported
commonly perceiving pressure from owners to prescribe
antimicrobials, especially in aggressive animals where
diagnostic work-up and futher treatment options were
limited by the patients’ behavior [16].
Potentiated aminopenicillins were still by far the most
commonly applied antimicrobials in 2018. Use of poten-
tiated aminopenicillins instead of non-potentiated ami-
nopenicillins was also a common reason for lack of
compliance with guidelines in cats with aURTD and
FLUTD. It should be mentioned that, in 2018, no oral
preparations of non-potentiated aminopenicillins regis-
tered for cats were on the market in Switzerland,
whereas in 2016, a preparation was available on the mar-
ket. This likely dissuaded veterinarians from following
the guidelines in cases of uncomplicated urinary tract in-
fections. In cases with aURTD, doxycycline is also listed
as a first-line treatment. However, doxycycline was rarely
prescribed despite its activity against Chlamydia sp. in-
fection, possibly due to the potential risk of esophageal
strictures in cats [53, 54].
Nevertheless, use of non-potentiated aminopenicillins
recommended as first-line treatment option for all three
disease complexes increased from 2016 to 2018 [41]. A
comparably high percentage of non-potentiated amino-
penicillins was prescribed in private practices in 2018.
Preparations authorized for subcutaneous application
accounted for most of these treatments. After discharge,
veterinarians had to switch to oral preparations of po-
tentiated aminopenicillins. Because this was classified as
serial therapy in the study, the increase in serial/combin-
ation therapy in 2018, especially evident in private prac-
tices and in cases with aURTD, should therefore be
interpreted with caution.
In cases with an indication for antimicrobial treatment,
the proportion of correct treatment decisions did not
increase. As described before, unjustified use of potenti-
ated instead of non-potentiated aminopenicillins was a
common reason for non-compliance. Difficulties to
orally administer medications to cats and fear of non-
compliance of the owner could be other reasons, favor-
ing the use of 3rd generation cephalosporins, which can
be injected as depot preparation (Convenia®, Zoetis,
Delémont, CH) [55]. A recent interview-based study in
Dutch companion animal veterinarians found that in
case of aggressive animals, veterinarians prefered inject-
able antimicrobials and long-acting formulations [16].
According to this study, other reasons to select antimi-
crobials different from those recommended in the guide-
lines were personal preferences, a lack of familiarity with
the guidelines or statements that the guidelines were
unclear or impractical.
Treatment duration in our study was also often in dis-
agreement with the guidelines, especially in cases with
abscesses. Antibiotics were often prescribed for a longer
duration than recommended. Overall, there is a lack of
controlled studies to investigate optimal antimicrobial
treatment duration in companion animal medicine, and
recommendations in current guidelines are commonly
extrapolated from human medicine [56]. This could re-
sult in believing that the recommended durations are
not sufficient for a treatment success. Furthermore,
shorter treatments may require check-up consultations
to assess the success of treatment, thus causing add-
itional costs to animal owners [17].
In cases where antimicrobials were not indicated, the
proportion of treatments in compliance with guidelines
Hubbuch et al. BMC Veterinary Research          (2020) 16:229 Page 7 of 13
increased from 35.6 to 54.0%, showing that unjustified
antimicrobial use has declined for the investigated dis-
eases. A study analyzing antimicrobial treatments of cats
presented to Flemish small animal practices also noted a
decrease of unjustified antimicrobial use, as well as an
increase in compliance with the guidelines after their
introduction [9]. In a study in human medicine, it was
shown that the time period under investigation after im-
plementation of guidelines has a great impact on the re-
sult: whereas 100% of the urinary tract infections were
treated as recommended right after the introduction of
guidelines, only 39% of prescriptions followed the guide-
lines after 1 year [57]. In our study, prescriptions were
assessed in 2016 and 2018 over a 1 year period, which
should provide a representative figure of the prescription
habits. In the Flemish study, the follow-up period was
not clearly specified [9].
Various differences in antimicrobial prescription habits
between the university hospitals and private practices
were apparent. First, as in 2016, HPCIAs were less com-
monly used at the university hospitals than in private
practices [45]. Second, the proportion of cases treated
with antimicrobials was lower at the university hospitals
compared to private practices and the decrease in anti-
microbial prescriptions was more pronounced. Third,
antimicrobials were more commonly withheld at the
universities in cases where antimicrobial treatment was
not indicated. Finally, diagnostic work-up was more
commonly performed at the universities as already re-
ported in 2016 [45]. These findings indicate a trend to-
wards a more restrictive use of antimicrobials at the
university hospitals, which is important, as they could
serve as role models for veterinary students and referring
veterinarians. Despite this, overall compliance with the
guidelines did not improve at the university hospitals
from 2016 to 2018.
In private practices, urine sediment analysis or bacter-
ial culture from an aseptically collected urine was more
commonly performed in 2018 and could have contrib-
uted to the reduction of antimicrobial prescriptions in
cases with FLUTD. Bacterial culture of urine should be
further promoted, since it could prevent unnecessary
antibiotic administrations. Costs of antimicrobial sensi-
tivity testing and difficulties to obtain samples for bac-
terial cultures were reported to be reasons why
veterinarians refrain from performing diagnostic work-
ups [55, 58]. Bacterial cystitis is considered to be rare in
cats, with reported prevalences of 3–15% in cats pre-
sented with FLUTD [56, 59–61]. Bacterial cystitis was
much more common in cats with FLUTD in this study.
This was also the case when diagnoses based on urine
sediment analysis were excluded and only cases with a
positive bacterial culture result were considered (31.0%
in 2016, 33.3% in 2018). Our results are, however, in
agreement with a study in Norway that also reported
bacteriuria in 33% of cats presented with FLUTD [62].
In private practice, PCR testing for feline herpesvirus-
1 and feline calicivirus in cases with aURTD was rarely
performed in both evaluation periods (2018: 1.9% of
cases; 2016: 1.1% of cases) [45]. The reason for this is
unknown, but additional costs could be a limitation.
One could argue that positive PCR test results for feline
calicivirus do not affect treatment of cats with aURTD.
However, in a confirmed feline herpesvirus-1 infection,
topical or systemic antiviral treatment could be applied
and potentially reduces the need for antibiotics [63].
Changes in prescription habits observed in this study
are overall encouraging, although mis- and overuse of
antimicrobials were still commonly observed. Further ef-
forts are necessary to foster prudent antimicrobial use in
companion animals in Switzerland. Since October 2019,
antimicrobial prescriptions in companion animals have
to be centrally registered in a national database (Infor-
mationssystem Antibiotika, IS ABV) [64]. This allows
monitoring of trends in antimicrobial use on practice/
clinic level and hopefully helps to increase awareness on
prudent use in veterinary medicine in Switzerland. Infor-
mation campaigns for animal owners in Switzerland on
the importance of responsible antimicrobial use have
been launched in 2015 [44], but they need to be futher
developed to reach their goals. Better availability of first-
line products on the Swiss market, and the development
of easy to administer first-line antimicrobials and bed-
side diagnostics for antimicrobial sensitivity testings are
future directions. Continued education programs for
practitioners support these efforts and encourage experi-
enced veterinarians to adapt their prescription habits to
current guidelines.
This study has some limitations. The true impact of
the online antimicrobial stewardship tool on antimicro-
bial prescribing of Swiss veterinarians cannot be un-
equivocally assessed, as different actions were
implemented in Switzerland as part of the national StAR
program to combat antimicrobial resistance starting in
November 2015. These actions, together with a generally
increased awareness of the importance of prudent anti-
microbial use among veterinarians could have contrib-
uted to the prescription changes observed in this study.
However, AntibioticScout.ch provides a user friendly de-
cision support tool informing veterinary practitioners in
a most direct and effective way. The investigated prac-
tices only represent a small proportion of practices in
Switzerland and their participation was on a voluntary
basis, which could have favored the inclusion of prac-
tices with more interest in prudent antimicrobial use.
Limited information in the patient records especially in
private practices impeded the evaluation of compliance
with the guidelines. Almost 50% of the cases obtained
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from private practices were not suitable for assessment,
mainly because of a lack of diagnostic work-up in cats
with FLUTD or because the clinical symptoms in cats
with aURTD and abscesses were not recorded. This
could have caused a selection bias towards the inclusion
of better documented cases and thus probably more se-
vere or complicated cases, in which the adherence to
prescription guidelines could have been hindered by co-
morbidities or other factors. Finally, data were analyzed
by different evaluators in 2016 and 2018; because judge-
ment of prudent antimicrobial use leaves some margin
of interpretation, this could have had an influence on
the results of the study.
Conclusions
A trend towards a more prudent antimicrobial use in
cats with aURTD, FLUTD and abscesses was found in
Switzerland in 2018, after the implementation of the
online antimicrobial stewardship tool AntibioticScout.ch.
Overall antimicrobial use, prescription of 3rd generation
cephalosporins in private practices and unjustified anti-
microbial use decreased from 2016 to 2018 for the
investigated disease complexes. Nevertheless, over-
prescription of antimicrobials and use of HPCIAs was
still common and overall compliance with the guidelines
still poor. Antimicrobial stewardship activities should
therefore be further promoted, and the availability of
first-line antimicrobials with a convenient application in
cats should be advanced.
Methods
This follow-up study evaluated diagnostic work-up and
antimicrobial prescription patterns for three feline dis-
ease complexes (aURTD, FLUTD, abscesses) in patients
presented between January 1st and December 31st 2018
using identical methods and data extraction procedures
from the same 14 veterinary practices and two university
hospitals as in a previously published study [45]. Anti-
bioticScout.ch was presented to the veterinarians
working in the participating university hospitals and pri-
vate practices at the beginning of the study in 2017.
Only private practices using OblonData® (Amacker&-
Partner Informatik AG, Zurich, Switzerland) or Diana
SUISSE® (Diana Software AG, Zurich, Switzerland) pro-
grams were eligible to participate. The electronic patient
records of all animals treated during the two study pe-
riods (2016 and 2018) were extracted from the practice
management system. At both university hospitals, re-
viewers had direct access to the electronical medical rec-
ord system. A full text search was conducted for the
predefined search terms (Table 4) and matches were
manually reviewed. Cases were selected based on defined
inclusion and exclusion criteria listed in Table 4 [45].
According to sample size calculation prior to the project,
92 patients per indication are required to detect a reduc-
tion in usage of an antimicrobial by 20%, given that this
antimicrobial is used in 50% of the patients with a par-
ticular indication (calculated with the software WinEpi-
scope 2.0 [65], a power of 80 and 95% confidence). We
therefore aimed to follow up on at least 100 patients per
indication, preferably 200 patients, to adjust for cluster-
ing of observations in different practices or clinics. At
both university hospitals, all cases that matched the cri-
teria were included, whereas in private practices, 16
cases per indication and practice were chosen using the
randomizer function of Microsoft® Excel (Microsoft
Corporation, Washington, USA) to avoid overrepresen-
tation of large practices. Only in private practices, cats
with abscesses were included because they are rarely
presented to university hospitals [45]. In two practices,
only 10 and 14 cases with aURTD and 10 and 6 cases
with FLUTD could be included in 2018 because of an in-
sufficient number of patients matching the inclusion cri-
teria. Data on medical history, clinical symptoms,
diagnostic work-up and details on antimicrobial therapy
and diagnosis were collected [45]. HPCIAs were defined
according to the World Health Organization (WHO) to
include third or higher generation cephalosporins,
Table 4 Inclusion and exclusion criteria and search terms for aURTDa, FLUTDb and abscesses
Indication Inclusion criteria Exclusion criteria Search terms
aURTDª Nasal discharge with infectious or unknown
etiology lasting no longer than two weeks
Evidence of fungal infection,
neoplasia or involvement of
the lower respiratory tract
Upper respiratory tract infection, rhinotracheitis,
rhinitis, sinusitis, nasal discharge, sneezing,
coughing, stridor, dyspnea, tachypnea, cat flu,
herpes, calici, mycoplasma, chlamydia, laryngitis
FLUTDb Stranguria, pollakiuria, periuria, pigmenturia or
dysuria and a diagnosis of bacterial cystitis,
bladderstones, urethrastones, urethral plugs,
idiopathic cystitis or cystitis of unknown origin
Involvement of the upper
urinary tract
Lower urinary tract disease, FLUTDb, pollakiuria,
polyuria, anuria, stranguria, dysuria, hematuria,
bloody urine, urinary stones, bladder stones,
urolithiasis, concrements, cystitis, urethra
obstruction, urinary tract infection, UTI, urinary
incontinence
Abscess Bite abscesses or abscesses of unknown origin Anal gland abscesses, tooth
root abscesses, foreign body
abscesses
Abscess, bite wound, bite, pus
As published by Schmitt et al., 2019 [45]; ªaURTD, acute upper respiratory tract disease; bFLUTD, feline lower urinary tract disease
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quinolones, macrolides, ketolides, glycopeptides and
polymyxins [66]. Combination therapy was defined as
prescription of two or more antimicrobial classes at a
time, whereas serial therapy was defined as consecutive
prescription of two or more antimicrobial classes [45].
Pretreated cases included both, cases referred from other
institutions and treated for the actual disease, as well as
cats presented to the same institutions and pretreated
for unrelated diseases.
Compliance with Swiss guidelines published in
December 2016 in the online tool AntibioticScout.ch
was evaluated [41–43]. For this purpose, indication, anti-
microbial class, dose and treatment duration were evalu-
ated and compared with the recommendations given in
the guidelines as detailed in Table 5. Cases with insuffi-
cient documentation or diagnostic work-up to judge
compliance with the guidelines were excluded from this
analysis. Cases from 2016 and 2018 were reviewed by
different evaluators. To assure consistency in judgment,
the evaluators adhered strictly to the criteria listed in
Table 5. Criteria not mentioned in the guidelines (e.g.
the character of nasal discharge in cats with aURTD)
were not considered. Undefined cases were discussed be-
tween evaluators to reach a consensus. To assess interra-
ter reliability, 60 cases (30 cases from 2016 and 2018
each) were assessed independently by two evaluators
with an observed Cohen’s kappa of 0.975 (standard error
of 0.025; 95% CI of 0.926–1.000) [67].
For a comparison of the two evaluation periods (2016
and 2018), data were grouped into cases where
antimicrobials were indicated (guidelines followed−/not
followed) and cases where antimicrobials were not indi-
cated (guidelines followed−/not followed, Table 6). This
allowed to account for different proportions of cases
presented with and without an indication for antimicro-
bial therapy in the two evaluation periods. Treatment
decisions were defined as correct or incorrect based on
Swiss guidelines.
For statistical analysis, IBM SPSS Statistics 23® (IBM,
New York, USA) and the software R version 3.6.1 (R
Foundation for Statistical Computing, Vienna, Austria
[68]) were used. A Mann-Whitney U Test was per-
formed to compare continuous data such as age and
treatment duration between the two evaluation periods.
Categorical variables (university hospital versus private
practice, sex, breed, pretreatment, hospitalization, diag-
nostic work-up, local wound treatment, drainage, indica-
tion for antimicrobial use, antimicrobial treatment,
prescribed antimicrobial classes and use of HPCIAs,
serial or combination therapy) were presented as
proportions with Clopper Pearson 95% CI, which were
calculated with the command binom.test() [68]. A mixed
effects logistic regression model (lme4 package [69]) was
used to compare compliance with the guidelines be-
tween 2016 and 2018 and between the disease com-
plexes (aURTD, FLUTD, abscess). Analysis was done
separately for cases with and without indication for anti-
microbial use (Table 6). The binary outcome consisted
of whether or not a prescription was in agreement with
the guidelines. In the multivariable model, year and indi-
cation (aURTD, FLUTD or abscesses), were included as
fixed effects. Based on our research question and expert
Table 5 Swiss prudent use guidelines for cats with aURTDa, FLUTDb and abscesses
Indication Comment Antibiotic Dosage
(mg/kg)
Application
frequency
Treatment
duration
(days)
aURTDa AMUc is only indicated if poor general condition, fever (≥ 39.5°C), lethargy
and/ or anorexia are present.
Doxycycline 10 / 5 SIDd/BIDe 5–14
Amoxicillin 15–20 BIDe/TIDf 5–14
FLUTDb AMUc is only indicated in case of UTIg (defined as presence of bacteriuriah
in patients with clinical signs of cystitisi);
AMUc is not indicated in patients with indwelling urinary catheters;
Complicated UTIg is defined as infection caused by anatomical or
functional changes or disorders of the immune system
Uncomplicated UTIg:
Amoxicillin
11–15 BIDe/TIDf 5–7
Complicated UTIg:
Amoxicillin/ Clavulanic
acid
12.5–20 BIDe/TIDf 5–28
Abscess AMUc is only indicated if signs of generalization (i.e. fever≥ 39.5°C), poor
general condition, severely contaminated wounds, and/or proximity to
delicate tissues (e.g. joints, thorax, abdomen, abscesses extending into deep
tissue) are present
Amoxicillin 15–20 BIDe 5–7
Amoxicillin/ Clavulanic
acid
12.5–20 BIDe 5–7
Cefalexin 20–30 BIDe/TIDf 5–7
Clindamycin 10–15 BIDe 5–7
Cefazolin 20 BIDe 5–7
Consistent with the Swiss prudent use guidelines presented in December 2016 as previously published [45], additional details used to faciliate judgement are
given in italics; in April 2019 the Swiss prudent use guidelines have been revised; aaURTD, acute upper respiratory tract disease; bFLUTD, feline lower urinary tract
diseases; cAMU, antimicrobial use; dSID, once daily; eBID, twice daily; fTID, three times daily; gUTI, urinary tract infection; hPresence of bacteria in the urine
sediment analysis or positive bacterial culture results from an aseptically collected urine sample (by cystocentesis or catheterization); iPresence of stranguria,
pollakiuria, periuria, pigmenturia or dysuria
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knowledge, we decided to include both explanatory vari-
ables in the multivariable model. Additionally, an inter-
action between year and indication was tested with a
likelihood ratio test with the package lmtest (cit) [70].
The different hospitals and practices were included as
random effects.
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deviated from the guidelines, cases were listed in “different antimicrobial class”
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